compound synthesis (WuXi AppTec)
WuXi AppTec is a verified supplier 
WuXi AppTec manufactures this product 
90
Structured Review
WuXi AppTec
compound synthesis
Compound Synthesis, supplied by WuXi AppTec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/synthesis+of+compounds/chemical+synthesis/pm40379660-333-13-10
Average 90 stars, based on 1 article reviews
Compound Synthesis, supplied by WuXi AppTec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/synthesis+of+compounds/chemical+synthesis/pm40379660-333-13-10
Average 90 stars, based on 1 article reviews
compound synthesis - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Selection:Article Title: Identification of novel and potent inhibitors of SARS-CoV-2 main protease from DNA-encoded chemical libraries. Article Snippet: After three rounds of selection, four highly enriched binders of which one ( Article Title: Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML. Article Snippet: Acute myelogenous leukemia (AML), a heterogeneous disease of the blood and bone marrow, is characterized by the inability of myeloblasts to differentiate into mature cell types.. Dihydroorotate dehydrogenase (DHODH) is an enzyme well-known in the pyrimidine biosynthesis pathway and preclinical findings demonstrated that DHODH is a metabolic vulnerability in AML as inhibitors can induce differentiation across multiple AML subtypes.. As a result of virtual screening and structure-based drug design approaches, a novel series of isoquinolinone DHODH inhibitors was identified. Article Title: Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models Article Snippet: We also thank Article Title: Discovery of a Novel [6-6-5-5-6] Pentacyclic Tetrahydrocyclopentaphthalazinone as a Promising PARP Inhibitor Scaffold. Article Snippet: Inhibitors of poly(ADP-ribose) polymerases (PARPs) have revolutionized the treatment of cancers with DNA repair deficiencies.. Here we describe the structure-based discovery and synthesis of 6−6−5− 5−6-fused pentacyclic scaffolds 5 and cis-(±)-6 as a novel class of PARP1 inhibitors.. Chiral supercritical fluid chromatographic separation of cis(±)-6 afforded inactive ent-6_P1 and active ent-6_P2. Next-Generation Sequencing:Article Title: Identification of novel and potent inhibitors of SARS-CoV-2 main protease from DNA-encoded chemical libraries. Article Snippet: After three rounds of selection, four highly enriched binders of which one ( Article Title: Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML. Article Snippet: Acute myelogenous leukemia (AML), a heterogeneous disease of the blood and bone marrow, is characterized by the inability of myeloblasts to differentiate into mature cell types.. Dihydroorotate dehydrogenase (DHODH) is an enzyme well-known in the pyrimidine biosynthesis pathway and preclinical findings demonstrated that DHODH is a metabolic vulnerability in AML as inhibitors can induce differentiation across multiple AML subtypes.. As a result of virtual screening and structure-based drug design approaches, a novel series of isoquinolinone DHODH inhibitors was identified. Article Title: Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models Article Snippet: We also thank Article Title: Discovery of a Novel [6-6-5-5-6] Pentacyclic Tetrahydrocyclopentaphthalazinone as a Promising PARP Inhibitor Scaffold. Article Snippet: Inhibitors of poly(ADP-ribose) polymerases (PARPs) have revolutionized the treatment of cancers with DNA repair deficiencies.. Here we describe the structure-based discovery and synthesis of 6−6−5− 5−6-fused pentacyclic scaffolds 5 and cis-(±)-6 as a novel class of PARP1 inhibitors.. Chiral supercritical fluid chromatographic separation of cis(±)-6 afforded inactive ent-6_P1 and active ent-6_P2. |